Zomato founder Deepinder Goyal’s private health-tech venture, Temple, has acquired London-based longevity practice Longévous to strengthen its clinical research. This move aims to add scientific credibility as the company prepares to launch its forehead-worn health wearable. The acquisition follows recent manufacturing partnerships and a valuation of $375 million.
Deepinder Goyal’s health-tech startup, Temple, has acquired the London-based longevity medicine practice Longévous. As part of this strategic acquisition, Longévous founders Dr. Robert Mohr and Dr. Avi Roy are joining Temple as Chief Medical Officer and Head of Science, respectively. This integration is a critical step for the company as it moves from the research and development phase toward a commercial product launch.
The acquisition serves to bridge the gap between consumer wearable data and clinical validation. By bringing in experienced medical professionals, Temple aims to sharpen the scientific rigor behind its upcoming health device. Dr. Mohr and Dr. Roy will focus on validating the company’s health claims and refining its scientific research, which is essential for a product that aims to track physiological markers like cerebral blood flow and oxygenation.
Temple is currently scaling its operations to prepare for its first consumer rollout. The company has finalized manufacturing partnerships with Zetwerk and Ethereal Machines to produce an initial run of several thousand units. This transition from laboratory prototypes to large-scale hardware manufacturing is a significant operational milestone for the startup, which is positioning itself in the premium health-tech segment.
As a private entity, Temple has attracted significant attention from the venture capital community. The company recently completed an employee stock option liquidity program, which valued the startup at $375 million. It has previously secured $54 million in seed funding from prominent investors, including Peak XV Partners and Steadview Capital. This financial backing provides the necessary capital to sustain the current scaling phase as the product approaches the market.
Investors and observers should note that the venture faces distinct challenges. The hardware market is capital-intensive, and scaling production involves complex supply chain and execution risks. Furthermore, Temple’s core health metric, described by the company as 'Entropy,' has faced scientific debate and skepticism from some medical professionals. The company’s ability to prove the clinical value of this biomarker against rigorous scrutiny will be a key factor in its commercial success.
The next major phase for the startup will be the commercial release of its forehead-worn wearable device. Market interest will center on whether the company can successfully move from its experimental, venture-funded stage to a reliable, mass-market consumer product that meets the health expectations set by its leadership.